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Emerging lines of evidence suggest that in addition to
growth factors, the process of colorectal tumorigenesis
may also be driven by the upregulation of the inducible
form of cyclooxygenase-2 (COX-2), an enzyme respon-
sible for the conversion of arachidonic acid to PGEs. The
present study was undertaken to investigate the expres-
sion and activation of the HER family members, and to
explore the regulation of COX-2 expression by the
HER2 pathway in human colorectal cancer cells. Here,
we report that human colorectal cancer cell lines express
abundant levels of HER2 and HER3 receptors, and are
growth-stimulated by recombinant neu-dierentiation
factor-beta 1 (NDF). NDF-treatment of colorectal
cancer cells was accompanied by increased tyrosine
phosphorylation and heterodimerization of HER3 with
HER2. In addition, we demonstrated that HER2 and
HER3 receptors in colorectal cancer cells are constitu-
tively phosphorylated on tyrosine residues and form
heterodimeric complexes in the absence of exogenous
NDF. Inhibition of HER2/HER3 signaling by an anti-
HER3 mAb against the ligand binding site resulted in a
decrease in the levels of constitutively activated HER2/
HER3 heterodimers, and the unexpected reduction of
COX-2 expression. Activation of the HER2/HER3
pathway by NDF induced the activation of COX-2
promoter, expression of COX-2 mRNA, COX-2 protein
and accumulation of prostaglandin E2 in the culture
medium. Finally, we demonstrated that NDF promotes
the ability of colorectal cancer cells to survive in an
extracellular matrix milieu, such as Matrigel, and also to
invade through a 8 mm porous membrane. These
biological activities of NDF and its stimulation of cell
proliferation are blocked by a specific inhibitor of COX-
2. Taken together, our findings provide the first
biochemical evidence of a possible role of the COX-2
pathway in the mitogenic action of NDF in colorectal
cancer cells where it may be constitutively upregulated
due to the autocrine/paracrine activation of HER2/
HER3 heterodimers.
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Introduction
Accumulating evidence suggests that colorectal tumor-
igenesis may be regulated by the growth factor-
inducible form of cyclooxygenase-2 (COX-2), an
enzyme responsible for the conversion of arachidonic
acid to prostaglandins (Prescott and White, 1996;
Smith et al., 1996). PGEs appear to play a variety of
roles in the gastrointestinal tract, including participa-
tion in physiological secretion and motility, and also in
pathologic processes such as neoplasia (Kutchera et al.,
1996; Eberhart, 1994; DuBois et al., 1996). The
primary PGEs generated in the colorectum appear to
be PGE2 (Smith et al., 1996). Recent studies have
shown the increased levels of COX-2 and PGE2 in
colorectal adenocarcinomas compared to adjacent
normal-appearing mucosa (Kutchera et al., 1996;
Eberhart, 1994; DuBois, et al., 1996) and inhibition
of COX-2 enzyme by specific COX-2 inhibitors reduces
tumor formation, and regresses pre-existing tumors
(Boolbol et al., 1996; Sheng et al., 1997; Chiu et al.,
1997). The potential neoplastic role of COX-2
expression was demonstrated by Tsujii and DuBois
(1995). They demonstrated that cells expressing high
levels of COX-2 had increased tumorigenic potential
which could be reversed by COX-inhibitors. Using an
APC knockout mouse model, Oshima et al. (1996)
demonstrated that COX-2 expression is induced very
early in neoplastic progression, and showed dramatic
reductions in the number and size of intestinal polyps
by a specific COX-2 inhibitor. The levels of COX-2
expression and PGE2 are also induced by growth
factors such as EGF or TGF-a in a number of cell
systems, including rat intestinal epithelial cells (DuBois
et al., 1994) and HCA-7 colon cancer cells (Coey et
al., 1997). In brief, these observations suggest a central
role of COX-2 in colorectal cancer cells.
Proto-oncogenes are a group of normal genes that
play important roles in the regulation of cell
proliferation. Abnormalities in the expression, struc-
ture, or activity of proto-oncogene products contribute
to the development and maintenance of the malignant
phenotype. Evidence that the gene products of several
activated proto-oncogenes are either growth factor
receptors or growth factors has suggested a possible
link between proto-oncogenes and growth factor
pathways (Ullrich and Schlessinger, 1990). For
example, c-erbB1 encodes the receptor of human
EGF receptor (HER1) which is overexpressed in a
number of epithelial tumor cells (Ullrich and Schles-
singer, 1990). The second member of HER family,
designated as HER2, shares extensive sequence
homology to HER1, predominantly in the tyrosine
kinase domain (Hynes and Stern, 1994; Graus-Porta et
al., 1997; Pinkas-Kramarski et al., 1997; Alroy and
Yarden, 1997). HER2 has been shown to be over-
expressed or amplified, or both, in a number of human
malignancies, including breast and ovarian cancer
(Hynes and Stern, 1994). Recently, two more
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members, HER3 and HER4, have been added to the
HER family as these receptors also share sequence
homology with the tyrosine kinase domain of HER1
(Hynes and Stern, 1994; Graus-Porta et al., 1997;
Pinkas-Kramarski et al., 1997). Regulation of the HER
family of receptors is complex. These receptors can be
transactivated in more than one fashion in a ligand-
dependent manner. For example, binding of neu
dierentiation factor beta-1 (NDF)/heregulin to
HER3 or HER4 can activate the HER2 receptor as a
result of HER2/HER3 or HER4/HER2 heterodimeric
interactions (Hynes and Stern, 1994; Alroy and
Yarden, 1997). HER1 and HER2 receptors have been
shown to induce transformed properties in recipient
cells (Reidel et al., 1988), possibly because of excessive
activation of signal transduction pathways. In contrast,
transformation by HER3 or HER4 receptors requires
the presence of HER2 or HER1 (Zhang et al., 1996).
Although the transforming potential of HER2 is well-
established, the mechanism involved remains poorly
understood. It has been proposed that this may involve
a constitutive activation of the intrinsic tyrosine kinase
activity due to either mutations in the HER2 gene and/
or transactivation via receptor-dimerization with other
members of the HER2 family (Hynes and Stern, 1994).
HER3 is unique amongst HER2 family members as it
has an impaired tyrosine kinase domain due to the
substitution of three amino acids (Guy et al., 1994;
Sierke et al., 1997). In spite of the kinase-dead nature
of HER3, NDF has been shown to increase HER3
tyrosine phosphorylation. This is most likely due to
formation of a high-anity co-receptor complex
through heterodimeric interaction with HER2 (Carr-
away and Cantley, 1994; Horan et al., 1995). Among
the HER family, it is believed the HER2/HER3
complex elicits the most potent mitogenic signal
(Carraway et al., 1995; Pinkas-Kramarski et al.,
1996). This may be related to the fact that the c-
terminal phosphorylation domain of HER3 contains
several consensus sites for the binding of signal-
transducing proteins implicated in mitogenic signaling.
Growth factors and their receptors play an essential
role in the regulation of the proliferation of colonic
epithelial cells. Human colorectal carcinomas and
colorectal carcinoma-derived human cell lines are
known to express HER1 and TGF-a (Coey et al.,
1987; Anzano et al., 1989; Untawale et al., 1993).
Although the significance of HER2 and HER3
receptors is fairly well established in breast cancer,
very little is known about their roles in conferring a
growth advantage in colorectal neoplasia. In one study,
Ciardiello et al. (1991) detected HER3 mRNA in 55%
primary or metastatic colorectal cancers as compared
to 22% in normal colon mucosa. In addition to HER2,
gastrointestinal tumors have been found to express
intense staining of HER3 protein (Yang et al., 1997;
Rajkumar et al., 1993). Kapitanovic et al. (1997) have
demonstrated that HER2 is widely overexpressed in
colorectal cancers as compared to normal mucosa, and
that the amount of overexpression correlates with
disease stage and patient survival. Although recent
studies have demonstrated the wide occurrence of
HER2 expression and COX-2 deregulation in human
colorectal cancer cells, it remains unknown whether
there is any role of NDF or the HER2/HER3 pathway
in the deregulation of COX-2.
Here we report that human colorectal cancer cell
lines express abundant levels of HER3 and HER2
receptors, and that colorectal cancer cells are growth-
stimulated by NDF. We observe that HER3 and
HER2 receptors are constitutively activated and form
HER2/HER3 heterodimeric complexes (in the absence
of any exogenous NDF) in colorectal cancer cells,
which express and secrete a 40 kDa protein which is
immunorecognized by a specific anti-heregulin mAb.
Inhibition of HER3 ligand binding site by an anti-
HER3 mAb resulted in a decrease in the levels of
constitutive HER2/HER3 heterodimers, and an un-
expected reduction of COX-2 expression. We also
demonstrate that activation of the HER2/HER3
pathway by exogenous NDF induces the expression
of COX-2 mRNA, COX-2 protein and the accumula-
tion of PGE2 in culture medium. Finally, we show that
NDF promotes the ability of colorectal cancer cells to
survive in an extracellular matrix milieu, and to invade.
These biological activities of NDF and its stimulation
of cell proliferation are blocked by a specific inhibitor
of COX-2. Taken together, our findings provide the
first biochemical evidence of a possible mediatory role
of the COX-2 pathway in NDF-mediated mitogenesis
and invasiveness in colorectal cancer cells where it may
be constitutively upregulated due to autocrine/para-
crine activation of HER2/HER3 heterodimers.
Results
Expression of HER family members in human colorectal
cancer cells
To investigate the possible significance of receptor
tyrosine kinases in colorectal cancer, we examined the
expression of HER family members in a panel of
widely used colorectal cancer cell lines. The results
presented in Figure 1A demonstrate that HER2
receptor is relatively overexpressed compared to
HER1 receptor among the colorectal cancer cell lines
used here, and CaC02 and LS174T cells also co-
overexpress HER3 receptor in addition to HER2
receptor. Interestingly, co-overexpression of HER2
and HER3 receptors in CaC0-2 and LS174T cells
was accompanied by increased expression of c-myc as
well as tyrosine phosphorylation of protein(s) in the
range of 180 kD. To examine the status of HER family
member in colorectal tumors, we analysed a small
number of residual colorectal specimens. Results in
Figure 1B demonstrate that HER2 and HER3
receptors were overexpressed as compared to HER1
in five out of eight tumor specimens, and thus in-part
validating the recent reports by Ciardiello et al. (1991)
and Kapitanovic et al. (1997).
To further explore the significance of HER2 and
HER3 receptors in colorectal cancer cells, we selected
LS174T and CaCo-2 since these cell lines co-express
both HER2 and HER3 receptors. We first examined
the responsiveness of colon cancer cells to exogenous
NDF. As demonstrated in Figure 2, NDF treatment of
LS174T and CaCo-2 cells leads to a 2 – 4-fold growth
stimulation over a period of 48 h (Figure 2A), and also
rapid (15 min) tyrosine phosphorylation of about
180 kDa protein (Figure 2B). It was interesting to
note that the faster migrating 180 kDa tyrosine
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phosphorylated band in LS174T and CaCo-2 cells was
responsive to exogenous NDF as it became a slower
migrating protein band after stimulation of the cells
with NDF (Figure 2B).
Next we examined the identity of the HER family
members whose tyrosine phosphorylation may be
enhanced by NDF stimulation of colorectal cancer
LS174T cells. Control and NDF-treated lysates were
immunoprecipitated with specific antibodies to HER2,
HER3 or HER4 and Western blots were probed with
anti-Phos-tyrosine mAb. As shown in Figure 2C, the
HER2 receptor had significant baseline tyrosine
phosphorylation and NDF treatment further enhanced
the tyrosine phosphorylation of HER3 and HER2, but
not the HER4 receptor. The low level of HER4 in
LS174T cells was also confirmed by immunoblotting
the above blot in Figure 2C with an anti-HER4 mAb
(data not shown).
Constitutive activation of the HER2/HER3 pathway in
colorectal cancer cells
To understand the biochemical basis of the observed
baseline tyrosine phosphorylation of HER2 and HER3
receptors (Figure 2C), we hypothesized that colorectal
cancer cells may express polypeptide(s) that may
activate HER family members in an autocrine/
paracrine manner. If this is true, chemical cross-
linking of HER receptors should result in the
formation of an HER2/HER3 heterodimer in the
absence of any exogenous NDF. Data in Figure 3A
demonstrate the constitutive formation of a tyrosine
phosphorylated HER2/HER3 heterodimeric complex
in LS174T cells, and the level of tyrosine phosphoryla-
tion of HER2/HER3 complex was further increased by
stimulation of cells with exogenous NDF (Figure 3A).
We used immunoblotting of total lysates after cross-
linking to visualize the dimers to over come the
problems of low eciency of immunoprecipitation.
Similar methodology has been used earlier to visualize
cross linked complexes. Reprobing of the above blots
with anti-EGFR mAb showed a lack of HER1 (HER1/
HER2) at this resolution in the HER2/HER3 complex
(data not shown).
In order to understand the possible nature of the
cellular-derived factor(s) that may regulate the
observed constitutive activation of HER2/HER3
receptors, we next explored the possibility of endogen-
ously secreted HRG or HRG-like ligand(s) on the
formation of HER2/HER3 dimers in LS174T cells,
using an anti-HER3 mAb against the HRG binding
site on HER3 receptor (Chen et al., 1996). As
illustrated in Figure 3B, pretreatment of cells with
anti-HER3 mAb resulted in a significant inhibition of
heterodimerization between HER3 and HER2 and this
was also true when cells were stimulated with NDF.
Colon cells secrete heregulin/heregulin like ligand
We then explored the possibility of expression of
heregulin in metabolically-labeled CaCo-2 and LS-
174T cells. Cell lysates and serum-free conditioned
medium (24 h) were immunoprecipitated with a
specific anti-heregulin beta-1 mAb. As can be seen
in Figure 4A, colorectal cancer cells express and
secrete a protein with an approximate molecular mass
of 40 kDa that is immunorecognized by anti-heregulin
mAb. To further verify the expression of heregulin in
CaCo2 and LS174T cells, we examined the express of
HRG transcript(s) by Northern hybridization using a
human heregulin 1.8 kb cDNA as a probe. Breast
cancer line MDA-MB-231 which express three HRG
transcripts (1.7, 2.6, and 6.8 kb) were used as a
positive control (Wen et al., 1992). As illustrated in
the Figure 4B, both CaCo2 and LS174T cell express
albeit levels of two smaller HRG transcripts (1.7 and
2.6 kb). Taken together, these observations suggested
that CaCO-2 and LS174T cells express and secrete
HRG which may be involved in the observed
constitutive activation of HER2/HER3 via autocrine/
paracrine pathway.
Eect of constitutive activation of HER2/HER3
receptors on COX-2 expression
Since the HER2/HER3 pathway is constitutively
activated in colorectal cancer cells, and COX-2 is
widely deregulated in colon cancer, we explored the
Figure 1 Expression of HER family members in colorectal cancer cell lines and tumor samples. One hundred mg of total
protein lysate was separated on a SDS–PAGE gel and blotted with the indicated antibodies. (A) Colorectal cancer cell lines. (B)
Human tumor specimens
NDF induces COX-2 expression
R Vadlamudi et al
307
potential role of baseline activation of HER3 in the
constitutive COX-2 expression in LS174T cells. Results
in Figure 5A show that treatment of LS174T cells with
mAb against the HER3 ligand binding site was
accompanied by a 50% inhibition of COX-2 expres-
sion when compared to cells treated with control
mouse IgG (compare lane 2 with lane 1). The observed
inhibition of COX-2 expression by inclusion of anti-
HER3 mAb (lane 2) in complete culture medium (10%
serum) was comparable to inhibition of COX-2
expression attained by complete serum-free medium
(lane 3). These results suggest that COX-2 expression
may be positively regulated by interaction of HER3
receptor with cellular-derived NDF or NDF-like
ligands, and also by serum factors. Indeed, data in
lane 4 (Figure 5A) confirm that exogenous NDF
Figure 2 NDF stimulates growth of colon cancer cells. (A)
Subconfluent cells were incubated with various concentrations of
NDF and cell growth was measured after 48 h by MTT-dye
uptake method by determining the optical density (OD) at a
wavelength of 570 nm. (B) Cell extracts (100 mg protein) were
analysed for tyrosine phosphorylation by blotting with a Phos-
tyrosine mAb. (C) LS174T cell lysates were immunoprecipitated
with anti-HER2, HER3, HER4, and analysed by SDS–PAGE.
Immunoprecipitates were then blotted with a Phos-Tyrosine mAb.
Results shown are representative of four times with similar results
Figure 3 HER2/HER3 pathway is constitutively activated in
colon cells. (A) Constitutive formation of HER2/HER3 dimer.
Monolayers of LS174T cells were incubated with or without NDF
and cross-linking was performed with 3 mM BS3 for 45 min.
Total lysates (300 mg) were subjected to SDS–PAGE blotted with
HER2, HER3 and Phos-tyrosine mAbs. M, monomer; D, dimer;
and IB, immunoblotting. How ever we observed a non specific
band in HER3 probed blot present in all the four lanes, and
shown by NS. (B) Blockade of constitutive HER2/HER3 dimer
formation with an anti-HER3 mAb (Ab5). LS174T cells were
pretreated with anti-HER3 mAb and cross-linking was performed
with 3 mM BS3 and then electrophoresed and immunoblotted as
described above
Figure 4 Expression of HRG in colorectal cancer cells. (A)
LS174T and CaCo-2 cells were metabolically labeled with 35S-
methionine for 16 h. Cell lysates (Lys) and conditioned medium
(CM) were immunoprecipitated with an anti-heregulin beta-1
mAb (HRG) and analysed by SDS–PAGE followed by
fluorography. Lane 5, CM from LS174T cells was immunopre-
cipitated with control IgG. Results shown are representative of
three experiments with similar results. (B) Total RNA (75 mg)
from the indicated cell lines was analysed by Northern
hybridization. The blot was stripped and reprobed with GAPDH
probe as a control. Three known isoforms present in positive
control MDA-MB-231 cells are shown by arrows. Size of RNA
markers (BRL) are indicated on the left
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induces the expression of COX-2 protein by threefold
in LS174T cells (compare lane 4 with lane 3). Similarly,
serum starvation of LS174T cells resulted in very low
or undetectable levels of COX-2 mRNA (Figure 5B,
compare lane 2 with lane 1). Furthermore, addition of
exogenous NDF in serum-free medium restored
mRNA levels comparable to those of normal cells
growing in 10% serum (compare lane 3 with lanes 1
and 2). These results suggest that expression of COX-2
is possibly regulated by constitutively activated the
HER2/HER3 pathway.
NDF induces COX-2 expression and PGE2 biosynthesis
In the next series of experiments we characterized the
regulation of the COX-2 pathway by NDF. Cell
extracts from NDF-treated and control LS174T cells
were analysed for the activation of HER3 and the
expression of down-stream target gene products such
as c-myc, and COX-2 protein. As illustrated in Figure
6A, the kinetics of NDF-mediated activation of HER3
receptors coincided with the stimulation of the
expression of c-myc and COX-2 protein. Similarly, in
CaCo-2 cells, NDF treatment also stimulated the
expression of COX-2 protein (Figure 6B) and COX-2
mRNA (Figure 7A). The observed NDF-mediated
stimulation of COX-2 expression in colorectal cancer
cells was functional, as there was a significant increase
in the levels of accumulated PGE2 in the culture
medium in NDF-treated CaCo-2 cells compared to the
PGE2 levels in the control culture medium (Figure 6C).
However the observed increase in the COX-2 protein
was not accompanied by concomitant increase in the
accumulation of PGE2 in the medium but a delay was
observed with maximum levels reaching at 24 h. The
delay in the accumulation of PGE2 in the medium
could be due to culturing of the cells in the low serum
conditions and such conditions are known to reduce
the activity of the other component enzymes in the
PGE2 pathway and delay PGE2 secretion (Chen et al.,
1997). The observed stimulation of PGE2 secretion in
NDF-treated colorectal cancer cells was mediated
through COX-2, as it could be eectively blocked by
a specific COX-2 inhibitor, NS-398 (Ciardiello et al.,
1991) (see Figure 9D).
To determine whether this increase in the level of
COX-2 protein in NDF-treated colorectal cancer cells
is associated with an increased expression of COX-2
mRNA Northern blot analysis was performed. Figure
7A shows that NDF treatment increased the steady-
state levels of 4.6 kilobase mRNA of COX-2 by 2 – 4-
fold in CaCo-2 cells (compare lane 1 with lanes 2 and
3). Co-treatment of cultures with cycloheximide, a
protein synthesis inhibitor, superinduced the COX-2
mRNA by twofold when compared to cycloheximide-
mediated stabilization of COX-2 mRNA (Figure 7A;
compare lane 5 with lane 6). Pretreatment of cells with
actinomycin D (transcription initiation inhibitor) also
prevented NDF-mediated increased COX-2 expression
(compare lanes 3 and 4 with lane 6). These results
indicate that COX-2 mRNA expression is regulated by
NDF at the pretranslational level.
To further confirm the role of NDF in the
transcriptional regulation of COX-2 gene, we transi-
ently transfected chimeric luciferase gene fused with 5’
region of COX-2 promoter (Kutchera et al., 1996) and
Figure 5 Constitutive activation of the HER2/HER3 pathway
upregulates the expression of COX-2. (A) Subconfluent LS174T
cells, cultured in the presence of 10% serum (lanes 1 and 2) or
0% serum (lanes 3 and 4), were treated with control IgG (lane 1),
anti-HER3 mAb (lane 2) or NDF (lane 4). Total lysates were
subjected to SDS–PAGE and blotted with anti-COX2 mAb.
Quantitation of the COX-2 band is shown in the bottom panel.
(B) Regular (lane 1) and 24 h serum-starved (lanes 2 – 3) LS174T
cells were treated with or without NDF (50 ng/ml); COX-2
mRNA was analysed by Northern blotting
Figure 6 NDF induces COX-2 expression and PGE2 biosynthesis. (A) LS174T and (B) CaCo-2 cells were incubated with
NDF (50 ng/ml). Total lysates (100 mg protein) were subjected to SDS–PAGE and blotted with HER3, COX-2 and c-myc
mAb. (C) CaCo-2 cells (80% confluent) were treated with NDF (50 ng/ml) for the indicated times and PGE2 levels were
assayed by RIA
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the activity of the promoter was assayed in the
presence or absence of NDF. In these studies, we
used murine fibroblast NIH3T3 cells which express no
or undetectable levels of HER3 were used as a negative
control (Carraway et al., 1995). As illustrated in the
Figure 7B, CaCo-2 cells showed high basal COX-2
promoter activity even in the absence of exogenous
ligand and its activity was further stimulated by NDF
treatment. However, in control NIH3T3 cells, the
COX-2 promoter activity was not stimulated by
NDF. Since CaC0-2 cells have very high levels of the
basal activity, we examined the eect of NDF on
COX-2 promoter activity in two other colorectal
cancer cell lines FET and LS174T showed four- and
tenfold less basal activity respectively, as compared to
CaCo-2 cells, and NDF can eectively stimulate the
level of COX-2 promoter activity to 2 – 3-fold (Figure
7B). The NDF treatment (4 h) of FET cells which
express both HER2 and HER3 receptors also resulted
in induction of expression of COX-2 mRNA (data not
shown). The higher COX-2 promoter basal activity in
CaCo-2 also correlated well with higher COX protein
levels. These results show that NDF/NDF like factors
can up regulate COX-2 promoter activity in colorectal
cancer cells and thus confirms the regulation of COX-2
by transcriptional mechanism. In brief, our results
demonstrate that the HER2/HER3 pathway induces
COX-2 mRNA, protein expression and PGE2 bio-
synthesis in human colorectal cancer cells.
Expression of COX-2 in dierent cell-types treated with
HRG
To examine if NDF also induces COX-2 in cells other
than colon, we treated breast (MCF-7, MDA-453) and
ovarian (SKOV-3) cell lines with exogenous HRG. As
shown in Figure 8, HRG treatment did not induce the
COX-2 mRNA expression in breast and ovarian cells
but induced the stimulation of c-myc mRNA expres-
sion, another potential target of HRG action.
However, TPA (phorbol ester) a known inducer of
COX-2 expression induced COX-2 mRNA in breast
and ovarian cell lines suggesting presence of functional
COX-2 gene in these cell lines. These results suggest
that HRG mediated COX-2 accumulation in colon
cells may be a tissue specific eect and this may be
related to either stabilization of COX-2 mRNA or
potential contribution of tissue-specific transcription
factors in colon cancer cells. These possibilities are
being investigated as a part of a separate study.
Figure 7 NDF regulates COX-2 gene at the transcriptional level. (A) CaCo-2 cells were treated with cycloheximide (50 mg/ml) or
actinomycin-D (20 mg/ml) in the presence or absence of NDF (100 ng/ml) for 6 h, except lane 1 (3 h). Total RNA was isolated as
described in the Materials and methods section and levels of COX-2 mRNA was detected by Northern blotting. Quantitation of
COX-2 mRNA is shown in the bottom panel. (B) Luciferase reporter gene containing 5’ region of COX-2 gene was transiently
transfected in to various cell lines and luciferase activity was measured after 36 h of transfection. Cell were treated for 6 h with
NDF where indicated before lysis. Luciferase activity was normalized with b-gal activity. Data are means of two transfections and
error bars represent standard error of means. Experiments with LS174, FET and NIH3T3 are repeated three times with similar
results
Figure 8 NDF specifically induces COX-2 mRNA in colorectal
cancer cells. Indicated cell lines were treated with or with out
NDF or TPA (phorbol ester) for 4 h. Total RNA (25 mg) was
analysed by Northern analysis using COX-2 cDNA as probe as
described in Figure 7. Blots were stripped and reprobed with c-
myc cDNA (bottom panels in A and B)
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Inhibition of NDF-mediated mitogenesis and invasiveness
by a COX-2 inhibitor
To investigate the significance of COX-2 in the action
of NDF in colorectal cancer cells we examined the
eect of a specific COX-2 inhibitor, NS-398, on NDF-
mediated growth stimulation of LS174T cells. We have
used NS-398 at a concentration of 20 mM in our
experiments based on the earlier studies showing
specificity and concentration required for specific
inhibition of COX-2 (Coey et al., 1997). The results
shown in Figure 9A demonstrate that co-treatment
(4 h) with NS-398 inhibited NDF-induced increased
cell growth in LS174T cells. Since transformed colonic
epithelial cells are known to survive in an extracellular
matrix milieu such as MatrigelTM, we also evaluated the
eect of NS-398 on the ability of LS174T cells to form
colonies in MatrigelTM. As shown in Figure 9B,
treatment with NS-398 resulted in a significant
inhibition of NDF-mediated increase both in the
number and size of colonies. Treatment with NDF
also promoted the ability of LS174T cells to invade
through 8 mm MatrigelTM-coated filters and this
phenotypic eect of NDF was suppressed by NS-398
(Figure 9C). The observed blocking eect of NS-398
on the biological action of NDF was due to the
inhibition of COX-2 enzyme in NDF-treated cells, as
cotreatment with NS-398 suppressed the stimulation of
PGE2 release by NDF (Figure 9D). Taken together,
these observations suggest a possible mediatory role of
the COX-2 pathway in NDF-stimulated mitogenic
responses in colorectal cancer cells.
Discussion
Activation of kinase activity associated with receptor
tyrosine kinases by ligand binding is thought to be the
common mechanism by which transmembrane recep-
tors for growth factors transduce signals that activate
cell proliferation. Growth factor receptors such as
HER1 and HER2 play an essential role in the
regulation of the proliferation of colonic epithelial
cells. Emerging lines of evidence suggest that in
addition to growth factors, the process of colorectal
tumorigenesis may also be driven by the upregulation
of the inducible form of cyclooxygenase-2 (COX-2), an
enzyme responsible for the conversion of arachidonic
acid to PGEs. The present study was undertaken to
investigate the expression and activation of the HER
family members, and to explore the regulation of
COX-2 expression by the heregulin/HER3 pathway in
human colorectal cancer cells.
The results presented here indicate that NDF is very
potent mitogen for colorectal CaCO-2 and LS174 cells
which express both HER2 and HER3 receptors.
Treatment with exogenous NDF enhance the levels of
tyrosine phosphorylation of HER3 and HER2 receptors
Figure 9 Inhibition of the biological eects of NDF in colorectal cancer cells by a COX-2 inhibitor. (A) Serum-starved LS174T
cells were treated with NDF (50 ng/ml) for 4 h in the presence or absence of COX-2 inhibitor NS398, (20 mM, suboptimal
concentration, ref. Tsujii and Dubois, 1995). NS-398 was added to the medium 30 min before the addition of NDF for and
untreated cells were treated with DMSO control. Cell growth was measured by MTT-dye uptake method by determining the optical
density (OD) at a wavelength of 570 nm as described in Figure 2. (B) Inhibition of NDF-stimulated cell survival by NS-398 in
MatrigelTM assay. Cells were plated in MatrigelTM and colony formation was counted after 48 h. (C) Inhibition of NDF-mediated
invasion by NS-398. After 48 h, cells which migrated through the MatrigelTM layer and the 0.8 mm membrane were counted. (D)
Inhibition of NDF-mediated PGE2 release by NS-398. The amount of PGE2 in the medium was measured after 24 h of treatment.
Each data point is a mean of two independent experiments performed in duplicate except in B where n=6
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over the easily detectable baseline levels of endogenous
receptor activation. Our conclusion that colorectal
cancer cells may secrete factors that activate HER2/
HER3 receptors in an autocrine/paracrine manner is
supported by the following evidence: (i) constitutive
activation of HER2 and HER3 receptors on tyrosine
residue (Figure 2B and C); (ii) formation of HER2/
HER3 heterodimers in the absence of any exogenous
HRG (Figure 3A); (iii) a reduction in the levels of
baseline HER2/HER3 heterodimers, tyrosine phosphor-
ylation of HER3 upon treatment with anti HER3 mAb
against ligand binding site (Figure 3B); and (iv) CaCo-2
and LS174T express and secrete of a protein with an
approximate molecular mass of 40 kDa immune-
recognized by a specific anti-HRG beta-1 mAb
(Figure 4). Taken together, these findings provide new
evidence in support of constitutive activation of the
HER2/HER3 pathway and growth-stimulation of
colorectal cancer cells by autocrine/paracrine heregulin
or related factors. In the past, there were examples of
enhanced expression of heregulin in mouse and human
mammary epithelial cells transformed by HER2
(Martin et al., 1987), but constitutive formation of
HER2/HER3 dimers has not been previously described.
At the moment, we do not know the basis of the
enhanced expression of heregulin in colorectal cancer
cells, and whether there is any contribution of other
pathways that are commonly deregulated in colorectal
cancer, e.g. mutations in the APC gene and activation
of Src (Prescott and White, 1996).
The finding that incubation of colorectal cancer cells
with an anti-HER3 mAb against the NDF binding site
results in a significant suppression of baseline
expression of COX-2 expression is important, as it
suggests that autocrine/paracrine activation of HER2/
HER3 by cellular-derived factors such as heregulin
may be involved in the regulation of COX-2 in
colorectal cancer cells. We have demonstrated that
the activation of HER3 receptor by recombinant HRG
was accompanied by in-parallel stimulation of expres-
sion of COX-2 mRNA and COX-2 protein, as well as,
PGE2 synthesis. The regulation of COX-2 mRNA by
NDF appears to be transcriptional, as it is super-
induced by cycloheximide and partially inhibited by
actinomycin D. This view is further supported by the
observation that NDF can enhance induction of COX-
2 promoter activity in three colon cells. The induction
of COX-2 pathway by NDF may have functional
implications in colorectal cancer cells, as both the
growth-stimulatory and invasiveness eects of NDF
were completely blocked by a specific COX-2 inhibitor.
The observation that the constitutive expression of
COX-2 by endogenous NDF, or related factors which
also regulate the growth of colorectal cancer cells,
raises the possibility that the reported variations of
basal COX-2 expression among dierent colorectal
cancer cells could be due, in part, to variable degrees of
interaction between endogenous NDF and HER2/
HER3 receptors. It is possible that the endogenous
NDFs and/or overexpressed HER2 family members
could act as one potential cellular factor(s) that
controls the action of the COX-2 protein. This is
important because HER2 and HER3 have been shown
to be widely overexpressed in human colorectal cancer,
and this fact may have functional implications in the
deregulation of the COX-2 pathway (Yang et al., 1997;
Rajkumar et al., 1993; Kapitanovic et al., 1997 and this
study).
Data from the literature suggest that COX-2 may
also be positively regulated in some cells with mutated
APC gene and/or activated Src family members, as
both of these events are common in colorectal cancer
(Prescott and White, 1996). In this context, it is
significant to note that inclusion of anti-HER3 mAb
completely prevented the formation of HER2/HER3
heterodimers, but only inhibited the levels of COX-2
protein by 50% compared to COX-2 expression in
control cells. Therefore, it is possible that factors other
than heregulin, i.e., activation of Src family members,
may play a role in the observed COX-2 expression in
anti-HER3 mAb-treated colorectal cancer cells either
directly or indirectly via interaction with the carboxyl-
region of the HER3 receptor. Alternately, it is also
possible that overexpressed HER2/HER3 receptors
may be partially activated intracellularly by endogen-
ous ligands like the binding of v-sis to the PDGF-
receptor in v-sis-transformed NRK cells (Keating and
Williams, 1988), and thus by-pass the inhibition by
exogenous anti-HER3 mAb. Further investigations are
needed to determine the possible contribution of other
pathways, and also signal-transduction pathways
utilized by heregulin to regulate COX-2 expression.
Another significant finding of this study is the
suppression of the mitogenic and invasive action of
heregulin in colorectal cancer cells by a specific
inhibitor of COX-2. Since inclusion of NS-398 to the
culture of LS174T cells also prevented the stimulatory
eect of heregulin on the release of PGE2 in the
culture medium our results would suggest that COX-2
possibly may play a mediatory role in the action of
heregulin in colorectal cancer cells. There is precedence
for the role of COX-2 in the mitogenic eect of
another growth factor, EGF (Coey et al., 1997).
Although overexpression of HER2 has been linked to
cellular transformation and proposed to have a role in
tumor progression in breast cancer cells (Lupu et al.,
1995), our finding is the first to demonstrate both the
mitogenic and invasive actions of heregulin in color-
ectal cancer cells, and its blockade by a specific
inhibitor of COX-2, a well identified target in
colorectal cancer. Taken together, our results raise
new questions: (i) about the nature of signaling
pathway(s) that may be involved in the regulation of
COX-2; (ii) the possible molecular basis of cell type-
specific regulation of COX-2 by NDF in colorectal
cancer cells; and (iii) at what point in colorectal
tumorigenesis the HER2/HER3 pathway is activated
and its relationship to the upregulation of COX-2 and
development of malignant phenotype.
Materials and methods
Cell cultures and reagents
Human colorectal carcinoma cell lines DiFi (Mandal et al.,
1997; LS174T, CaCo-2, SW480, HT-29, SW613 and
HCT116 (Mandal et al., 1997), FET (Brattain et al.,
1984; Mandal et al., 1998), and breast cancer SKBR3
(Kumar et al., 1991) cells were maintained in DMEM-F12
(1 : 1) supplemented with 10% fetal calf serum. Antibodies
against EGFR (# MS320-P1), HER2 (# MS-301-P1),
HER3 (# MS262-P), HER4 (# MS-270-P1), c-myc (#MS-
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130-P0), heregulin beta 1 (# RB-276-P0, original source Dr
Yosef Yarden) and HER3 ligand binding site
(# MS303PA) were obtained from Neomarkers Inc.,
Recombinant NDF-beta 1 (Kumar et al., 1996) was
obtained from the Amgen. MAbs against COX-2
(#C22420), and Pho-tyrosine (# 4G10) were obtained
from Signal Transduction and UBI, respectively.
Cell extracts
For preparation of cell extracts, cells were washed 36 with
phosphate buered saline and lysed in buer (50 mM Tris-
HCl, pH 7.5; 120 mM NaCl; 0.4% NP-40; 100 mM NaF;
200 mM NaVO5; 1 mM PMSF; 10 mg/ml leupeptin; 10 mg/ml
apotinin) for 15 min on ice. The lysates were centrifuged in
an Eppendorf centrifuge at 48C for 15 min. Cell lysates
containing equal amounts of protein were resolved on a
7% SDS – PAGE, transferred to nitrocellulose, and probed
with the appropriate antibodies by using an ECL method
or alkaline phosphatasebased color reaction method
(Kumar et al., 1991; Kumar and Atlas, 1992).
Metabolic labeling and immunoprecipitation
An equal number of cells were metabolically labeled for
16 h with 100 mCi/ml 35S-methionine in methionine-free
medium containing 2% FBS in the absence or presence of
mAb 225 and treated as indicated. Cells extracts were
prepared as described above. Cell extracts containing an
equal amount of total trichloroacetic acid perceptible
counts were immunoprecipitated with the desired or
control Ab, resolved on a SDS – PAGE gel, and analysed
by autoradiography (Kumar and Atlas, 1992).
MatrigelTM and invasion assays
Cell survival and the ability to form colonies in an
extracellular matrix (MatrigelTM; Becton Dickinson) were
assayed according to Sheng et al. (1997). Cells were
suspended in a DMEM:MatrigelTM (1 : 1) solution and
poured on top of the thin gel layer in a 48 well plate. Cells
were grown for 48 h at 378C and the colonies formed were
counted using an inverted microscope.
Cell invasion assays were performed as described
previously (Adam et al., 1994), with few modifications and
by using modified Boyden diusion chambers containing a
8 mm porous membrane (Becton Dickinson). Conditioned
medium obtained from NIH3T3 cells was used as a
chemoattractant and was placed in the lower chamber.
LS174T cells were serum starved for 24 h, trypsinized and
placed in the upper chamber and treated with NDF in the
presence or absence of COX-2 inhibitor. After 48 h the
membranes were fixed and stained with DAPi. Cells that
invaded and migrated to the lower surface were counted by
using a Leica fluorescent microscope.
Chemical cross-linking
Cross-linking was performed according to Chen et al.
(1996) and Fanger et al. (1989) with some modifications.
Monolayer cells were incubated at 48C with or without
NDF (100 ng/ml) for 2 h. Cross-linking was performed at
48C with 3 mM BS3 (Pierce). After 45 min of incubation,
the reaction was quenched with the addition of ammonium
acetate (20 mM final concentration), washed with PBS and
lysed with lysis buer. Total protein lysate (300 mg) was
separated on a 6% SDS – PAGE and immunoblotting was
performed with HER3, HER2 and Phos-tyrosine mAb.
Northern hybridization and COX-2 promoter-luciferase assays
Total cytoplasmic RNA was analysed by Northern
hybridization using a complementary DNA probe
(Oxford Biomedical Research) for human COX-2 mRNA
as described (Kumar and Atlas, 1992). For HRG
expression, a 1.8 kb human NDF a2b cDNA insert was
used as a probe (Wen et al., 1992). 28S and 18S RNA were
used to assess the integrity of the RNA and for RNA-
loading control. COX-2 luciferase construct was obtained
from Dr Steve Prescott and Luciferase assay were
performed as described (Kutchera et al., 1996) with some
modifications. Colon cells were serum starved in low serum
medium (DMEM containing 0.1% serum) for 48 h before
transfection. Serum starved colon cells were transiently co-
transfected with COX-2 luciferase plasmid and control pSV
b-Gal vector (Promega) using Lipofectamine (GIBCO).
The transfection eciency was normalized by cotransfec-
tion with pSV b-Gal vector (Promega). Luciferase activity
was measured 36 h after transfection using luciferase assay
kit (Promega). Where indicated cells were treated with
(NDF 100 ng/ml) for 6 h before lysis.
PGE2 synthesis
Cells were grown in 60 mm plates to 80% confluence and
serum starved for 48 h. Fresh medium (5 ml) containing
0.2% BSA was added and cells were treated with NDF
(100 ng/ml). At indicated times, medium was collected and
the amount of PGE2 was determined by PGE2 [125I] RIA
kit (Perspective Diagnostics) (Granstrom and Kindahl
1978). PGE2 concentration was normalized to total
protein.
Abbreviations
NDF, recombinant neu-dierentiation factor-beta 1; COX-
2, cyclooxygenase-2; mAb, monoclonal antibody; PGE2,
prostaglandin E2.
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